EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF A HYPOLIPIDEMIC AGENT (CGP-43371) IN HEALTHY-SUBJECTS

被引:5
|
作者
SUN, JX
CIPRIANO, A
CHAN, K
KLIBANER, M
JOHN, VA
机构
[1] Drug Development Department, Pharmaceuticals Division, Ciba-Geigy Corp, Ardsley, New York
关键词
D O I
10.1002/jps.2600830231
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The relative bioavailability of a capsule formulation and the effects of food on the pharmacokinetics of a hypolipidemic agent (CGP 43371) in 12 healthy subjects were examined. Each subject randomly received a single dose of 800 mg of CGP 43371, either as a dispersion formulation under fasting conditions or as a capsule formulation under fasting and fed conditions in a three-way crossover design with a washout period of 2 weeks between each treatment. Serial blood samples were collected at frequent intervals up to 96 h after each treatment. The concentrations of CGP 43371 in plasma were determined by a normal-phase HPLC method. Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 mu g/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 mu g.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption. In contrast, the mean peak plasma drug concentration (2.01 mu g/mL) and area under the curve from time zero to infinity (57.35 mu g.h/mL) for the capsule formulation with food were enhanced similar to 11- and 14-fold, respectively, when compared with that without food. The corresponding mean lag time (2.1 h) was decreased similar to 50%. These differences in pharmacokinetic parameters were statistically significant, on the basis of an analysis of variance. On the other hand, the mean time to the peak plasma drug concentration (12.5 h) and terminal elimination half-life(17.7 h) were not significantly different. The results of this study demonstrated that the ingestion of a standard meal significantly increased the rate and extent of absorption but did not affect the elimination of CGP 43371.
引用
下载
收藏
页码:264 / 266
页数:3
相关论文
共 50 条
  • [1] Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics
    Sun, JX
    Walter, B
    Sandefer, EP
    Page, RC
    Digenis, GA
    Ryo, UY
    Cipriano, A
    Maniara, WM
    Powell, ML
    Chan, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (03): : 230 - 237
  • [2] EFFECT OF FOOD ON THE BIOAVAILABILITY OF CAPTOPRIL IN HEALTHY-SUBJECTS
    SINGHVI, SM
    MCKINSTRY, DN
    SHAW, JM
    WILLARD, DA
    MIGDALOF, BH
    JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (2-3): : 135 - 140
  • [3] THE DISPOSITION OF CGP-43371, A NOVEL HYPOLIPIDEMIC AGENT, IN FECES, PLASMA AND URINE FOLLOWING SINGLE ORAL DOSES TO NORMAL VOLUNTEERS
    MANLARA, WM
    POWELL, ML
    CIPRIANO, A
    SUN, J
    ULM, E
    SANDEFER, EP
    DIGENIS, GA
    FASEB JOURNAL, 1992, 6 (04): : A1001 - A1001
  • [4] THE EFFECT OF FOOD OR MILK ON THE BIOAVAILABILITY OF ETINTIDINE IN HEALTHY-SUBJECTS
    HUANG, SM
    MARRIOTT, TB
    WEINTRAUB, HS
    BOCCAGNO, JA
    ABELS, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1988, 26 (03) : 113 - 117
  • [5] RELATIVE AND ABSOLUTE BIOAVAILABILITY OF CIBENZOLINE CAPSULES AND TABLETS IN HEALTHY-SUBJECTS
    MASSARELLA, J
    SILVESTRI, T
    LIN, A
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (09) : 894 - 896
  • [6] FOOD REDUCES THE ORAL BIOAVAILABILITY OF PROPANTHELINE BROMIDE IN HEALTHY-SUBJECTS
    MOSES, DK
    CHARLES, BG
    RAVENSCROFT, PJ
    WHYTE, IM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (06) : 758 - 759
  • [7] DETERMINATION OF THE RIFAMYCIN-RELATED HYPOLIPIDEMIC DRUG CGP-43371 IN HUMAN FECES, PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    MANIARA, WM
    POWELL, ML
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 660 (01): : 135 - 142
  • [8] EFFECT OF FOOD ON THE BIOAVAILABILITY OF PENTOPRIL, AN ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR, IN HEALTHY-SUBJECTS
    RAKHIT, A
    HURLEY, ME
    REDALIEU, E
    KOCHAK, G
    TIPNIS, V
    COLEMAN, J
    ROMMEL, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (06): : 424 - 428
  • [9] RELATIVE BIOAVAILABILITY OF RIMANTADINE HCL TABLET AND SYRUP FORMULATIONS IN HEALTHY-SUBJECTS
    WILLS, RJ
    CHOMA, N
    BUONPANE, G
    LIN, A
    KEIGHER, N
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (12) : 886 - 888
  • [10] KINETICS AND BIOAVAILABILITY OF MEXILETINE IN HEALTHY-SUBJECTS
    HASELBARTH, V
    DOEVENDANS, JE
    WOLF, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (06) : 729 - 736